|
Jun 6
|
Why Is Techne (TECH) Down 3% Since Last Earnings Report?
|
|
Jun 6
|
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
|
|
Jun 6
|
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
|
|
Jun 5
|
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|
|
Jun 5
|
Global Markets Are On a Tear. These Stocks in Europe and Japan Are Still Bargains.
|
|
Jun 4
|
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.
|
|
Jun 3
|
AstraZeneca (LSE:AZN) Reports Positive Trial Results For ENHERTU® In Breast Cancer Treatment
|
|
Jun 3
|
UK Stocks That Might Be Priced Below Estimated Value
|
|
Jun 2
|
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
|
|
Jun 2
|
AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO
|
|
Jun 2
|
ASCO25: AstraZeneca’s novel trial design for camizestrant pays off in breast cancer
|
|
Jun 2
|
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
|
|
Jun 2
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
|
|
Jun 2
|
AstraZeneca Says DATROWAY Shows Promising Results in Combination Trials for Lung Cancer
|
|
Jun 1
|
IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
|
|
Jun 1
|
Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk
|
|
Jun 1
|
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
|
|
May 30
|
Danaher Partners With AstraZeneca to Support Precision Medicine
|
|
May 30
|
Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue?
|
|
May 30
|
Danaher and AstraZeneca to develop diagnostic tools and tests
|